의료용 모르핀 시장 규모 : 투여 경로별, 용도별, 최종 사용자별, 지역별 및 예측별

Global Medical Morphine Market Size and Forecast

According to Verified Market Research, the Global Medical Morphine Market size was valued at USD 27.96 Billion in 2025 and is projected to reach USD 45.30 Billion by 2033 growing at a CAGR of 7.98% from 2027 to 2033.

Medical morphine is extensively administered for the management of intense acute pain, including discomfort experienced after major surgical procedures, traumatic injuries, or myocardial infarction. It is also a cornerstone therapy in oncology, where it is prescribed to control both persistent and breakthrough pain in cancer patients. Within palliative and end-of-life care settings, morphine is essential for enhancing patient comfort and overall quality of life, as it alleviates not only severe pain but also distressing symptoms such as acute breathlessness. Market demand for medical morphine is largely propelled by the increasing incidence of chronic and life-limiting conditions, including cancer, advanced arthritis, and other terminal disorders. Additionally, the steady rise in the global elderly population who are at greater risk of developing such illnesses continues to contribute to the growth of this market.

Global Medical Morphine Market Definition

Medical morphine is a highly potent opioid medication administered in healthcare environments to manage moderate to intense pain. It is obtained from opium, a naturally occurring compound sourced from the seed pods of the opium poppy plant. With a long-standing history in clinical practice spanning more than a century, morphine continues to be a fundamental component of pain management protocols, particularly in hospital care, emergency treatment, postoperative recovery, oncology, and palliative settings. The drug exerts its effects through action on the central nervous system. It interacts with specialized receptors in the brain and spinal cord primarily mu-opioid receptors thereby diminishing the transmission of pain signals and modifying the brain's interpretation of discomfort. This mechanism leads to substantial pain relief and often induces a feeling of calmness. Alongside its analgesic properties, morphine may also produce sedation, relaxation, and, in some cases, a mild sense of euphoria.

Global Medical Morphine Market Overview

Medical morphine remains an essential opioid analgesic for the treatment of moderate to severe pain, particularly in postoperative settings, palliative care, and chronic conditions such as cancer-associated pain. By acting on the central nervous system, it effectively reduces pain intensity and enhances patient comfort and overall quality of life. Individuals with cancer especially in advanced stages often require potent opioid therapy as part of established pain management protocols. Owing to its proven efficacy, cost-effectiveness, and availability in diverse dosage forms including oral tablets, injectable formulations, and extended-release preparations, morphine is frequently recommended as a first-line opioid in clinical guidelines. The increasing global incidence of cancer, particularly among older populations, is therefore driving sustained demand for morphine-based therapies.

In addition, the expanding elderly demographic worldwide is a key contributor to market growth. Aging individuals face a higher risk of chronic conditions such as arthritis, cardiovascular diseases, musculoskeletal disorders, and neurological ailments, many of which are associated with persistent pain. The frequency of surgical procedures is also higher in this age group, leading to greater requirements for postoperative pain control. As morphine continues to play a pivotal role in both acute and long-term pain management, the global demographic shift toward an older population is directly supporting increased utilization across hospitals, specialty clinics, and long-term care institutions.

The growing volume of surgical procedures worldwide is a major factor driving demand for morphine. The increasing incidence of orthopedic operations, cardiac interventions, cesarean deliveries, and minimally invasive surgeries has heightened the need for reliable postoperative pain management. Owing to its strong analgesic potency and rapid onset of action, morphine continues to be a fundamental component of perioperative care. As healthcare systems in emerging economies strengthen their infrastructure and expand surgical capabilities, the corresponding requirement for opioid analgesics, including morphine, is rising steadily.

However, market growth is significantly constrained by the strict regulatory frameworks governing opioid medications. In many jurisdictions, morphine is classified as a highly controlled substance and is subject to rigorous oversight to prevent misuse, diversion, and dependency. Authorities often impose manufacturing quotas, mandate comprehensive documentation throughout the supply chain, and implement strict prescription monitoring systems. Although these regulations are critical for safeguarding public health, they can create logistical challenges, increase administrative responsibilities for healthcare providers, and contribute to cautious prescribing behaviors, thereby limiting market expansion.

Additionally, pricing constraints and reimbursement policies present further challenges. In numerous countries, morphine is designated as an essential medicine and is frequently subject to government-regulated pricing to maintain affordability. While such measures align with public health priorities, they can compress manufacturer margins and reduce incentives for investment in product development, capacity expansion, or innovation.

Global Medical Morphine Market: Segmentation Analysis

The Global Medical Morphine Market is segmented based on Route of Administration, Application, End Users, and Region

Global Medical Morphine Market, By Route of Administration

Oral

Injectables

Others

Based on Route of Administration, the market is segmented into Oral, Injectables, Others. Injectables segment accounted a highest market share in 2025. Injectable formulations hold a leading position owing to their fast onset of action and strong efficacy in controlling intense and acute pain. In clinical environments particularly during surgical procedures, trauma management, and emergency care injectable morphine is commonly selected because it delivers rapid analgesia and enables accurate dose titration. Administration through intravenous or intramuscular routes ensures reliable and consistent absorption, which is especially vital in critical care and palliative settings.

Furthermore, injectable morphine is predominantly utilized in inpatient facilities where patients are under continuous medical supervision. The ability of healthcare professionals to closely monitor therapeutic response and adjust dosing as needed reinforces the preference for injectable forms over oral and alternative administration routes.

Global Medical Morphine Market, By Application

Arthritis

Cancer

Myocardial Infarction

Kidney Stones

Diarrhea

Others

Based on Application, the market is segmented into Arthritis, Cancer, Myocardial Infarction, Kidney Stones, Diarrhea, Others. The Cancer segment accounted the highest market share in the year 2025. This segment leads primarily due to the substantial incidence of moderate to severe pain experienced in advanced stages of the disease. Morphine is extensively regarded as a foundational therapy for managing cancer-related pain, particularly within oncology and palliative care settings. Given that cancer-associated pain is frequently chronic and progressively worsening, sustained opioid treatment is often necessary, with morphine serving as a central component of such regimens. Its proven ability to alleviate both continuous and breakthrough pain plays a vital role in enhancing patient comfort and overall quality of life, thereby establishing the cancer segment as the dominant area of morphine utilization.

Global Medical Morphine Market, By End Users

Hospitals and Clinics

Ambulatory Surgical Centers

Homecare

Others

Based on End Users, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, Others. The Hospitals and Clinics segment accounted the highest market share in the year 2025. In these inpatient settings, morphine is frequently used to manage postoperative discomfort, support emergency care, and treat severe conditions such as myocardial infarction. The availability of skilled medical personnel allows for careful administration and close monitoring, which is especially critical when using opioid-based medications. Additionally, hospitals operate under structured clinical protocols and maintain secure storage and dispensing systems for controlled substances, ensuring regulated and consistent utilization. These factors collectively position hospital settings as the leading end users of medical morphine.

Global Medical Morphine Market, By Geography

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

On the basis of Geography, the global Medical Morphine market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The North America segment accounted the highest market share in the year 2025. This region maintains a leading position due to its sophisticated healthcare infrastructure, substantial healthcare spending, and well-established pain management standards. A strong network of pharmaceutical producers and advanced hospital systems facilitates regulated opioid supply and distribution. Moreover, relatively high awareness of palliative care services and cancer-related pain treatment supports steady demand for morphine. Although regulatory controls are stringent, they provide an organized framework that permits appropriate medical access for legitimate therapeutic applications. The integration of widespread clinical utilization, accessible healthcare services, and mature supply chain systems solidifies North America's dominance in the regional market landscape.

Key Players

The "Global Medical Morphine Market" study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are Mallinckrodt Pharmaceuticals, Alcaliber S.A., Sanofi, Johnson Matthey, Northeast Pharmaceutical Group Co., Ltd., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Cipla Inc., Mylan N.V., Fresenius Kabi USA, DAIICHI SANKYO COMPANY, Allergan, Pacira BioSciences, Inc., Endo Pharmaceuticals Inc., Tris Pharma, Inc., Purdue Pharma L.P., VERVE HEALTH CARE LTD., Taj Pharmaceuticals Limited, AbbVie Inc. among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL MEDICAL MORPHINE MARKET OVERVIEW
• 3.2 GLOBAL MEDICAL MORPHINE MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL MEDICAL MORPHINE MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL MEDICAL MORPHINE MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL MEDICAL MORPHINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL MEDICAL MORPHINE MARKET ATTRACTIVENESS ANALYSIS, BY ROUTE OF ADMINISTRATION
• 3.8 GLOBAL MEDICAL MORPHINE MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL MEDICAL MORPHINE MARKET ATTRACTIVENESS ANALYSIS, BY END USERS
• 3.10 GLOBAL MEDICAL MORPHINE MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL MEDICAL MORPHINE MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
• 3.12 GLOBAL MEDICAL MORPHINE MARKET, BY APPLICATION (USD BILLION)
• 3.13 GLOBAL MEDICAL MORPHINE MARKET, BY END USERS (USD BILLION)
• 3.14 GLOBAL MEDICAL MORPHINE MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL MEDICAL MORPHINE MARKET EVOLUTION
• 4.2 GLOBAL MEDICAL MORPHINE MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE GENDERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY ROUTE OF ADMINISTRATION

• 5.1 OVERVIEW
• 5.2 GLOBAL MEDICAL MORPHINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY ROUTE OF ADMINISTRATION
• 5.3 ORAL
• 5.4 INJECTABLES
• 5.5 OTHERS

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 GLOBAL MEDICAL MORPHINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 6.3 ARTHRITIS
• 6.4 CANCER
• 6.5 MYOCARDIAL INFARCTION
• 6.6 KIDNEY STONES
• 6.7 DIARRHEA
• 6.8 OTHERS

7 MARKET, BY END USERS

• 7.1 OVERVIEW
• 7.2 GLOBAL MEDICAL MORPHINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USERS
• 7.3 HOSPITALS AND CLINICS
• 7.4 AMBULATORY SURGICAL CENTERS
• 7.5 HOMECARE
• 7.6 OTHERS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 MALLINCKRODT PHARMACEUTICALS
• 10.3 ALCALIBER S.A.
• 10.4 SANOFI
• 10.5 JOHNSON MATTHEY
• 10.6 NORTHEAST PHARMACEUTICAL GROUP CO., LTD.
• 10.7 SUN PHARMACEUTICAL INDUSTRIES LTD
• 10.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
• 10.9 PFIZER INC.
• 10.10 CIPLA INC.
• 10.11 MYLAN N.V.
• 10.12 FRESENIUS KABI USA
• 10.13 DAIICHI SANKYO COMPANY
• 10.14 ALLERGAN
• 10.15 PACIRA BIOSCIENCES, INC.
• 10.16 ENDO PHARMACEUTICALS INC.
• 10.17 TRIS PHARMA, INC.
• 10.18 PURDUE PHARMA L.P.
• 10.19 VERVE HEALTH CARE LTD.
• 10.20 TAJ PHARMACEUTICALS LIMITED
• 10.21 ABBVIE INC. AMONG OTHERS.